Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model by Nörder, Miriam et al.
Modified Vaccinia Virus Ankara Exerts Potent Immune
Modulatory Activities in a Murine Model
Miriam No ¨rder




2,3, Carlos A. Guzma ´n
1*
1Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany, 2Institute of Virology, Technische Universita ¨t
Mu ¨nchen and Helmholtz Centre Munich, Munich, Germany, 3Clinical Cooperation Group Antigen Specific Immunomodulation, Technische Universita ¨tM u ¨nchen and
Helmholtz Centre Munich, Munich, Germany
Abstract
Background: Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine
delivery vector in preclinical and clinical studies against infectious diseases and malignancies. Here, we investigated whether
an MVA which does not encode any antigen (Ag) could be exploited as adjuvant per se.
Methodology/Principal Findings: We showed that dendritic cells infected in vitro with non-recombinant (nr) MVA
expressed maturation and activation markers and were able to efficiently present exogenously pulsed Ag to T cells. In
contrast to the dominant T helper (Th) 1 biased responses elicited against Ags produced by recombinant MVA vectors, the
use of nrMVA as adjuvant for the co-administered soluble Ags resulted in a long lasting mixed Th1/Th2 responses.
Conclusions/Significance: These findings open new ways to potentiate and modulate the immune responses to vaccine
Ags depending on whether they are co-administered with MVA or encoded by recombinant viruses.
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Introduction
Several poxviral vector systems are under clinical evaluation
for vaccine development against infectious diseases and cancer.
One of these vectors is based on the highly attenuated modified
vaccinia virus Ankara (MVA) that was originally obtained by
attenuation over more than 500 passages in chicken embryo
fibroblast cultures [1,2]. During its attenuation, MVA lost ,15%
of its parental genome, including genes that regulate viral host
range and evasion of host immune response. The replication in
most mammalian cells is extremely limited and in non-permissive
human cell lines only immature viral particles are formed
[2,3,4,5]. Therefore, dissemination within the host is precluded
in most species, including humans. MVA also showed an
excellent safety record when administered during the smallpox
eradication campaign in approximately 150,000 individuals,
including many persons at risk for the conventional pox vaccines
[6,7,8]. Recombinant MVA (rMVA) expressing immunogens
from a variety of infectious agents (e.g.,H I V ,Plasmodium
falciparum) or tumor-associated antigens (Ags) have been success-
fully tested in phase I and II clinical trials [9,10,11,12,13,14,15].
In spite of this, most commercial vaccines are based on
formulations encompassing purified Ag(s) and adjuvant(s). Thus,
considering the fact that the immune system has evolved to
respond to ‘‘danger’’ and that molecules delivering such a
‘‘danger’’ signal(s) (e.g., pathogen associated molecular patterns)
are currently been investigated as potential adjuvants [16], and
other viral vectors such as influenza virus has been investigated
for their adjuvant properties [17], we thought to evaluate whether
MVA could be also used as an adjuvant, since it should provide a
signal to the innate immune system for its recognition, as occurs
for other viruses [18,19,20,21].
Dendritic cells (DCs) are the major link between the innate and
the adaptive immune system, and MVA is able to target them in
vivo, which is a prerequisite in the induction of an adaptive
immune response, not only by MVA but also by other poxviruses
[22,23,24,25,26,27]. However, in vitro studies investigating the
effect of MVA on DCs showed contrasting results. Behboudi et al.
reported that rMVA induces DC dysfunction in the murine system
with stimulation of MHC class I down-regulation and apoptosis
[28], whereas Drillien et al. demonstrated moderate activation of
human DCs by MVA [29]. On the other hand, Kastenmu ¨ller et al.
carried out an in depth dissection of the characteristics of rMVA
infected human DCs, by analyzing their viability and maturation/
activation status. Surprisingly, human DCs infected when still
immature (iDC) were more prone to apoptosis or necrosis,
whereas mature DC (mDC) tolerate infection for longer periods
[30]. The iDC were also impaired in their maturation capacity.
The expression of activation markers was reduced in the
apoptotic/necrotic subpopulation of MVA infected mDC, where-
as in living mDC no down-regulation of co-stimulatory molecules
was detected [30]. Nevertheless, it is extremely difficult to perform
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conclusions, since many of the experimental parameters differed
(e.g., mouse versus human DCs, bone marrow derived versus
splenic DC, MOIs, incubation time, read-outs). Interestingly,
despite in vitro studies showing either activation or dysfunction,
most in vivo reports confirm that MVA is able to induce strong
immune responses. It was even postulated that the intrinsic
modulatory properties of poxviruses can be exploited for the
establishment of immune interventions [31]. Nevertheless, little
has been done to understand the underlying events to these
contrasting reports and only few systematic studies were carried
out to investigate the putative immune potentiating activities of
MVA [31,32,33]. Furthermore, the immune responses evoked
after co-administration of an Ag with non-recombinant (nr) MVA
as adjuvant have not been yet systematically dissected.
Here, we demonstrate that the differences in the findings in the
above mentioned in vitro studies are mainly due to the use of
different experimental settings, namely, the arbitrary selection of a
particular multiplicity of infection (MOI) which might in turn lead
to either impaired or enhanced DC function. In contrast to the
dominant T helper (Th) 1 responses which have been observed
using rMVA expressing target Ags, mice immunized by the
intramuscular (i.m.) route with ovalbumin (OVA) co-administered
with nrMVA elicited mixed Th1/Th2 responses. Interferon (IFN)-
c producing CD8
+ T cells and in vivo lymphocyte-mediated
cytotoxic activity were also preserved when OVA was co-
administered with nrMVA. The existence of long term immune
responses was shown by the presence of Ag specific B and T cell
responses even 3 months after the last immunization.
The results presented in this study suggest that nrMVA could be
an attractive tool to potentiate responses against co-administered
Ags, particularly taking into consideration its excellent safety
profile and the fact that it has been already approved for and used
in humans.
Results
Activation of murine DCs is dependent on the MOI of
nrMVA
Murine bone marrow (BM)-DCs were infected with nrMVA at
different MOIs (0.05, 0.5 and 5, which were in turn considered as
low, intermediate and high, respectively). The DC activation status
after infection was evaluated by assessing the expression of the co-
stimulatory molecules CD80 and CD86, as well as by their
capacity to present MHC class I and II restricted epitopes to
OVA-specific CD8
+ or CD4
+ T cells, respectively. At all tested
MOIs, DCs showed an increase in the expression of CD86 when
compared to the non-infected DCs, with the highest expression of
CD86 observed in cells infected with the intermediate MOI (MOI
0.5, 73% of CD86
hi ¸ Fig. 1). At the highest MOI tested CD86
expression was slightly higher than in non-infected cells (46% vs.
37% of CD86
hi ¸ Fig. 1), however, CD86 expression was
considerably lower than on DCs infected at the intermediate
MOI. As for CD86, CD80 showed the highest expression at
intermediate MOI (66%) followed by the lowest MOI (60%), but
in contrast to CD86, at the highest MOI tested, CD80 expression
was not higher than in non-infected DC (44% and 43%
respectively). The MHC class I complex that has a high basal
expression on non-infected cells showed an increased expression at
low MOI, but its expression inversely decreased with increasing
MOI in a dose-dependent manner. At the highest MOI tested, we
observed a lower expression of MHC I as compared to DCs
infected with the lower MOI (Fig. 1). A similar phenomenon was
observed for the expression of the MHC class II complex (data not
shown). We have also evaluated the effect of the MOI on cell
viability. We observed that the number of apoptotic cells (i.e.,
Annexin-V
+) increased with the MOI in a dose-dependent
manner. The same holds true for the number of dead cells (i.e.,
Annexin-V
+ and 7-AAD
+). Nevertheless, the number of live cells
at low and intermediate MOI was only slightly lower (80% and
71%, respectively) than the non-infected control cells (91%), but
there was a remarkable decrease in the number of living DCs after
infection at the highest MOI (13%; Fig. 1). Thus, we found that
there is a window for the optimal infection of murine BM-DCs in
vitro in order to achieve the maximum level of activation together
with a comparable low number of dead and apoptotic cells (an
schematic representation is shown in supplementary Fig. S1).
These observations might also explain some of the contrasting
results reported in the literature, since different studies were
performed using different MOI without carrying out an exhaustive
analysis of the optimal dose to be used in the experimental setting
to guarantee maximal activation and function of the DCs.
Improved Ag processing and presentation by DCs
infected in vitro at intermediate MOI of nrMVA add-
mixed with OVA
We then evaluated whether the effect of the MOI observed on
the activation markers and the viability is reflected in the Ag
presentation capacity of DCs. To this end, the capacity of MVA to
improve the ability of DCs to process and present OVA to Ag-
specific CD8
+ or CD4
+ T cells from OT-I or OT-II transgenic
mice was evaluated (Fig. 2). DCs pulsed with OVA and infected
with nrMVA at different MOIs were washed to eliminate MVA
which did not enter the cells. DCs were then further incubated for
16 h, washed and co-cultured with OVA-specific CD4
+ or CD8
+
T cells for 5 days. DCs pulsed with OVA and infected with
nrMVA at an intermediate MOI (i.e., MOI 0.5) were the most
efficient in stimulating both CD4
+ and CD8
+ T cells (p,0.001 and
p,0.01, respectively, at T cell:DC ratio of 6.25 as compared with
OVA alone, Fig 2). However, when the MOI is further increased
to 5, the Ag presentation capacity was significantly impaired
(Fig. 2).
A strong IgG production is triggered by using nrMVA as
adjuvant for soluble Ags
Next, we evaluated the capacity of nrMVA to act as adjuvant by
enhancing the immune responses against co-administered Ags. To
this end, the model Ag OVA was co-administered twice with
nrMVA to mice by the i.m. route on day 1 and 28. Mice
immunized with OVA plus nrMVA showed a strong OVA-specific
IgG production in comparison with control mice immunized with
either PBS or nrMVA (p,0.0001; Fig. 3A). Mice immunized with
OVA alone showed only a weak OVA-specific IgG response. Of
note, it is important to mention that the antibody (Ab) response
induced after co-administration of OVA and nrMVA is signifi-
cantly stronger than the Ab response obtained using rMVA-OVA
(p,0.0001, Supplementary Fig S2). On the other hand, the
subclass distribution of OVA-specific IgG showed that the
increment in the IgG levels was mainly due to IgG1 (Fig. 3B).
Mice immunized with OVA and nrMVA as adjuvant showed a
long-lasting Ab response. Due to the fact that the IgG subclass has
a half-life of approximately 3 weeks, we decided to investigate the
number of Ab-secreting cells (ASCs) in BM, which is known to be
responsible for the maintenance of Ab titers over long periods of
time [34,35]. Therefore, 3 months after the last immunization the
ability of BM cells to secrete total and OVA-specific IgG after 6 h
of re-stimulation was determined by ELISPOT assay. This short
MVA Exerts Adjuvant Activity
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B cells into ASCs; thus, only actively secreting plasma cells are
determined [36]. High numbers of OVA-specific IgG secreting
cells were observed in the BM of mice vaccinated with OVA co-
administered with nrMVA as adjuvant (Supplementary Fig. S3),
showing the long lasting effect of the vaccination.
We also analyzed the number of interleukin (IL)-4 secreting cells
present in the spleens from vaccinated mice after in vitro re-
stimulation with OVA. Splenocytes from animals immunized with
OVA alone did not show any significant difference with respect to
the control group, whereas those from mice receiving OVA co-
administered with nrMVA showed a significant increment in the
number of IL-4 secreting cells (p,0.05, Fig. 4A). These results
correlate with a stimulation of Th2 cells suggested by the IgG
isotype analysis.
Immunizations using nrMVA as adjuvant also stimulate
the induction of Ag-specific cytotoxic CD8
+ T cells
The cellular immune responses induced by the immunization
using nrMVA as adjuvant were further evaluated by assessing the
cytokine production by spleen cells re-stimulated in vitro with either
OVA protein or peptides. Co-administration of OVA with
nrMVA triggered the induction of IL-2 production by splenocytes
re-stimulated with OVA (p,0.05; Fig. 4B). The capacity of CD8
+
T spleen cells to produce IFN-c in response to the re-stimulation
with a peptide (SIINFEKL) encompassing a MHC class I
restricted immunodominant OVA epitope was also significantly
increased in mice injected with OVA plus nrMVA respect to those
receiving either PBS (p,0.0001) or OVA alone (p,0.0001), 400-
and 6-fold respectively (Fig. 4C). The level of IFN-c was also
increased in supernatants from splenocytes derived from mice
Figure 1. DCs viability and activation depend of the MOI of nrMVA. DCs were infected with nrMVA at different MOIs for 6 h. After washing
and further incubation for 16 h, changes in the expression of surface molecules on non-infected and nrMVA-infected DCs were measured by flow
cytometry. DC viability was assessed by FACS using Annexin-V (apoptotic cells) and 7-AAD (necrotic cells) after infection with nrMVA at different
MOIs. The MOI of 0.05, 0.5 and 5 were arbitrarily considered as representative of low, intermediate and high MOI, respectively. Data are representative
of 3 independent experiments.
doi:10.1371/journal.pone.0011400.g001
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OVA alone after in vitro re-stimulation with OVA protein (1199
and 404 pg/ml, respectively). Three months after the last
immunization, BM cells were isolated and used to determine
whether the observed IFN-c response was transient [37]. We
found that in mice vaccinated with OVA together with nrMVA
the number of IFN-c secreting cells was higher than in mice that
received OVA alone (p,0.05; data not shown), thereby demon-
strating that it was not a transient response, but rather long lasting
immunity. The effector function of CD8
+ T cells was then
examined by performing in vivo killing assays. One week after the
last immunization mice were injected by i.v. route with OVA
peptide-pulsed target spleen cells to assess the cytotoxic capacity in
vaccinated mice. Control mice immunized with PBS or nrMVA
alone showed no cytotoxic activity, whereas those which received
OVA alone showed a minimal cytotoxic response. In contrast,
Figure 2. DCs infected with nrMVA stimulate OVA presentation to T cells. DCs were infected for 6 h with nrMVA at a MOI of 0.05, 0.5 or 5 in
the presence of OVA protein (10 mg/ml). Non-stimulated and OVA pulsed DCs were used as controls. (A) After infection, DCs were cultured with either
naı ¨ve CD8
+ T cells from OT-I mice (left panel) or naı ¨ve CD4
+ T cells from OT-II mice (right panel) at different ratios for 5 days. Cells were pulsed with
[
3H]-thymidine 16 h before harvesting. Proliferation of T cells was assessed by measuring [
3H]-thymidine incorporation. (B) MVA-infected DCs were
cultured with CFSE labeled naı ¨ve T cells of OT-I (upper panel) or OT-II mice (lower panel) for 5 days. Proliferation was assessed by flow cytometry.
p,0.01 (**); p,0.001 (***).
doi:10.1371/journal.pone.0011400.g002
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a high Ag-specific cytotoxic response (80% lysis, p,0.01; Fig. 5).
This demonstrates that the use of nrMVA as adjuvant also induces
a strong CD8
+ T cell component. In addition, as observed with the
IFN-c response, the cytotoxic activity of CD8
+ T cells was retained
even 3 months after the last immunization in mice vaccinated with
nrMVA add-mixed with Ova (64% of lysis; data not shown).
Discussion
As attenuated virus, MVA possesses the ideal profile to be
investigated as adjuvant, since it could provide a signal to the
innate immune system for its recognition, as occurs for other
viruses [21]. In this study, we focused on investigating the
immunomodulatory properties of nrMVA by performing both in
vitro and in vivo studies.
A putative effect of MVA as adjuvant most probably relies on its
ability to target DCs [26]. Most of the current knowledge on the
interactions of poxviruses with DCs is derived from infection
studies of human DCs with the vaccinia virus. In this context, it
was reported that infection of monocyte-derived human DCs with
the vaccinia virus leads to an inhibition of their maturation,
phagocytic capacities and migration. Moreover, their capacity to
stimulate T cells in vitro seems to be markedly decreased
[23,38,39]. It was also shown that rMVA infection of DCs leads
to apoptosis, MHC class I down-regulation and impairment of
DCs ability to induce T cell proliferation [28]. On the other hand,
most of these effects are abrogated when gating on living DCs
[30]. The dissection of the specific effects triggered by rMVA
infection on iDCs and mDCs showed that iDCs are more prone to
apoptosis, which in turn leads to impaired function. It was
suggested that the lower dose required to infect iDCs might be
explained by their higher phagocytic capacities.
To address this issue in a systematic manner, we infected
murine derived BM-DCs with nrMVA in vitro at different MOI (i.e,
0.05 to 5), and assess their capacity to process and present
exogenously pulsed OVA as a model Ag. It is important to
highlight that in our studies we used nrMVA to assess the adjuvant
properties of MVA, whereas most studies reported in the literature
used rMVA encoding for different heterologous Ags. This might
influence, at least in part, the results obtained due to the fact that
protein Ags have different half-life as a result of glycosylation
patterns, signal peptides or also due to different expression
patterns (e.g. membrane-associated versus cytoplasmic protein).
Furthermore, some of the expressed Ags might have intrinsic
immune modulatory properties.
Our results demonstrate that DC activation after infection with
nrMVA tightly depended on the infectious dose used. When DCs
were infected in vitro with nrMVA at low MOI they became
activated and showed the ability to efficiently present OVA-
epitopes to Ag-specific naı ¨ve T cells, thereby inducing their
proliferation. In contrast, when DCs were infected with nrMVA
at a high MOI a reduction in the expression of MHC class I
molecules was induced with a concomitant increase in the
numbers of apoptotic and dead cells. This results in an impaired
capacity to present Ags to T cells, which is in turn in agreement
with previous studies [28]. Of note, infection with rMVA
expressing OVA at high MOI increases only slightly the number
of apoptotic cells and does not significantly affect the Ag
presentation functions of DCs (data not shown). This suggests
that the expression of a heterologous Ag might have a
considerable influence on cell viability and the final outcome of
the immune response following vaccination. Thus, the data
obtained using different rMVAs should not be directly extrap-
olated to either other rMVAs or to effects observed by using
nrMVA as adjuvant.
Our studies show that the infection of DCs with nrMVA at an
optimized MOI results not only in a strong activation of the DCs,
but also in a remarkable increased ability to act as APC.
Concerning the observed class I restricted responses, they can be
only explained by cross-presentation (i.e., the Ag is not produced
by the cell but given exogenously). However, it is yet to be
determined whether it was the result of a direct Ag cross
presentation or an ‘‘indirect’’ cross presentation of apoptotic cells
which have taken up the Ag. Most probably, both pathways are
involved to different extents. Independently of the underlying
mechanisms, our in vivo studies showed that co-administration of
nrMVA resulted in consistently enhanced immune responses
against the model Ag OVA. The obtained results demonstrate that
in contrast to the strong Th1 responses with low antibodies titers
which are reported after administration of rMVA-OVA [40], a
mixed Th1/Th2 response pattern was observed using nrMVA as
adjuvant. Co-administration of OVA with nrMVA was also able
Figure 3. The use of nrMVA as adjuvant triggers OVA-specific humoral responses. (A) OVA-specific IgG titers and (B) OVA-specific IgG1 and
IgG2c isotypes were determined by ELISA. Each bar represents the group mean end-point titer, the SEM is indicated by vertical lines. The results were
statistically significant at p,0.001 (**); p,0.0001 (***).
doi:10.1371/journal.pone.0011400.g003
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after re-stimulation with a MHC class I restricted OVA peptide ex
vivo, as well as a potent in vivo killing activity, thereby showing that
CD8
+ effector T cells are also stimulated following immunization.
The elicited responses were not transient, as demonstrated by the
detection of OVA-specific IFN-c secreting CD8
+ T cells and
cytotoxic activities 3 months after immunization.
In conclusion, we found that the differences on viability,
maturation phenotype and stimulatory potential of MVA-infected
DC observed in vitro as reported in the literature are most probably
due to the individual conditions used to infect DCs. The activation
of MVA is MOI dependent, and there is a window in which DC
activation and Ag presentation are optimal for the stimulation of T
cells. High MOI induced apoptosis and, as other authors
proposed, it might increase cross presentation by other non-
infected DCs, which in turn could play an important role in vivo.I n
addition, we showed that nrMVA per se is able to provide the
critical signals to the immune system to induce strong humoral
responses against a co-administered Ag in vivo, retaining the
desired Ag-specific cytotoxic activity usually evoked by rMVA.
Thus, considering the urgent need of new adjuvants and the fact
that the use of MVA has already demonstrated an impressive
safety profile in preclinical and clinical studies, nrMVA appears as
a promising candidate adjuvant for vaccine development.
Methods
Mice
Six to eight week old-female C57BL/6 mice were purchased
from Harlan Winkelmann GmbH (Borchen, Germany) and were
treated in accordance with local and European Community
guidelines. Mice were kept under specific pathogen-free conditions
in individual ventilated cages with food and water ad libitum. OT-I
mice expressing the OVA257–264/K
b-specific TCR and OT-II
mice expressing the OVA323–339/A
b specific TCR on C57BL/6
background have been described elsewhere [41,42,43]. Mice were
propagated and maintained in the animal facility at the HZI in
Braunschweig. Experiments using animals were done with the
permission of the local authorities; permission number:
509.42502/07-04.01, Bezirksregierung Braunschweig.
Figure 4. IL-4-, IL-2- and IFN-c-producing cells were stimulated
using nrMVA as adjuvant. Splenocytes of immunized mice were re-
stimulated in vitro for 48 h with the OVA protein to determine the
numbers of (A) IL-4- and (B) IL-2-secreting cells. (C) Cells were also
stimulated for 16 h with the dominant MHC class I restricted peptide
SIINFEKL to determine the numbers of IFN-c secreting CD8
+ T cells.
Results are presented as specific spot forming units (SFU)/1610
6 cells.
The SEM of quadruplicate values is indicated by vertical lines. The
values reported are those obtained from stimulated cells subtracted of
background from non-stimulated cells. Values of non-stimulated cells
were lower than 50 SFU/1610
6 cells. The results were statistically
significant at p,0.05 (*); p,0.0001 (***).
doi:10.1371/journal.pone.0011400.g004
Figure 5. T cell mediated cytotoxic activity was stimulated
using nrMVA as adjuvant. CFSE labeled control and target cells
pulsed with the OVA peptide (SIINFEKL) were transferred to vaccinated
mice. After 16 h, animals were sacrificed and specific lysis was analyzed
by flow cytometry. Results correspond to mean values of each group
(n=3) from one representative out of three independent experiments.
doi:10.1371/journal.pone.0011400.g005
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MVA(IInew), the vaccinia virus MVA cloned isolate optimized
for host range selection, was routinely propagated and titrated by
endpoint dilution in chicken embryo fibroblasts to obtain a 50%
tissue culture infectious dose [44]. The rMVA-OVA P7.5 was
obtained as previously described [27]. For in vitro and in vivo assays,
MVA wild type was purified by ultra centrifugation through a
36% sucrose cushion.
Ags and peptides
OVA (Sigma, USA) was used as Ag for the in vitro and in vivo
studies. The dominant T cell epitope recognized in context of
MHC class I molecules (H-2k
b), OVA257–264 peptide (SIINFEKL),
and the T cell epitope recognized in the context of MHC class II
(I-A
b), OVA323–339 peptide (ISQAVHAAHAEINEAGR), were
synthesized at the HZI (Braunschweig, Germany), as previously
described [45,46].
BM-derived DC culture and in vitro stimulation
BM-derived DCs were prepared from C57BL/6 mice using
recombinant murine granulocyte macrophage colony-stimulating
factor (GM-CSF; BD Pharmingen), as previously described
[47,48]. On day 6 of culture, cells were counted, mixed and
divided into 6-well plates to have 5610
6 cells/well. Only cultures
that showed more than 70% of CD11c
+ cells at day 6 were used
for experiments. DCs were infected with different concentrations
of MVA (MOI 0.05, 0.5 and 5) and/or pulsed with the model Ag
OVA (10 mg/ml) for 6 h. Then, DCs were washed 3 times with
PBS in order to remove unbound MVA and further incubated for
16 h. Thereafter, expression of DCs surface markers was analyzed
by FACS or functional assays were performed.
Flow cytometric analysis
The DC stimulation was evaluated by surface marker
expression by flow cytometry. Briefly, cells were incubated with
mouse Fc block (BD Pharmingen) at 4uC for 15 min. Cells were
stained with fluorescence-labeled antibodies diluted in FACS
buffer (PBS-BSA 1%). FITC-labeled mAb against mouse CD40
(3/23), CD80 (16-10A1), CD86 (GL1), H2-K
b (AF6-88.5) and I-
A
b (A6-120.1), as well as PE- or PE-Cy7-labeled mAb against
CD11c (HL3 and N418, respectively) were purchased from BD
Pharmingen and eBioscience. After 30 min of incubation at 4uCi n
the dark, cells were washed twice with FACS buffer. Cells were
resuspended, transferred to FACS tubes and kept on ice in the
dark until analysis, which was performed on a FACSCalibur or a
FACS Canto (BD Bioscience) using BD cell Quest
TMPro or FACS
Diva software and gating on CD11c
+ cells. The viability of the
stimulated DC was analyzed using ‘‘Vybrant
R Apoptosis Assay Kit
#2’’, according to the manufacturer’s instructions. Apoptosis and
dead of infected DCs were assessed by staining with Annexin V
labeled with AlexaFluor488 and 7-AAD, respectively. Analysis of
apoptotic/dead cells was done gating on CD11c
+ cells.
Proliferation assay
The effect of the different stimuli on Ag processing and
presentation by DCs was examined by the proliferation of Ag-
specific naı ¨ve T cells after co-culture with the differentially pre-
treated DCs. This test was performed using naı ¨ve T cells from
OT-I and OT-II transgenic mice. Spleens from OT-I and OT-II
mice were aseptically removed and pooled. Organs were
mechanically disaggregated in complete medium (RPMI 1640
supplemented with 10% heat inactivated fetal bovine serum,
100 U/ml of penicillin, 50 mg/ml streptomycin, 1 mM L-
glutamine) by gently pressing them through a 100 mm mesh using
a syringe plunger. The cell suspension was centrifuged and the
pellet was resuspended in ACK buffer to lyse erythrocytes. CD4
+
and CD8
+ T cells were isolated using the CD4
+ or CD8
+ T cell
isolation kit (Miltenyi Biotec) from OT-II and OT-I mice,
respectively. For the [
3H]-thymidine incorporation assay, the
pre-treated DCs were added in quadruplicates at different T
cells:DCs ratios (ranging from 6.25 to 50) to flat-bottom 96-well
culture plates. As positive controls, the DCs stimulated with either
the corresponding OVA peptides (0.1 mg/ml) or the OVA protein
(10 mg/ml) were used. Then, the co-cultured cells were incubated
at 37uC with 5% CO2 in a humidified atmosphere for 4 days.
Before harvesting, the cells were pulsed with [
3H]-thymidine
(1 mCi/well) for 16–18 h. The [
3H]-thymidine incorporated into
the DNA of proliferating cells was determined by a c-scintillation
counter (MicroBeta Trilux, Wallac). Results are expressed as the
arithmetic mean of [
3H]-thymidine uptake in cpm. For the CFSE
proliferation assay, T cells were labeled with 1 mM CFSE
(Molecular Probes). Labeling was stopped by adding fetal bovine
serum. After one wash in complete medium, T cells were adjusted
to 1610
6 cells/ml and 100 ml of the cell suspension was co-
cultured with pretreated DCs in 96-well plates. Cell suspensions
were seeded in round-bottom 96-well cell culture plate (TPP,
Switzerland). As positive control, T cells were stimulated with Con
A, as negative control T cells were cultured without stimulus in
complete medium. Plates were incubated for 5 days at 37uC with
5% CO2. On day 5, CD4
+ and CD8
+ T cells were stained with
PE-Cy7 labeled CD4 (RM4-5, eBioscience) and APC labeled CD8
(53–67, eBioscience) Abs, respectively. Proliferation was measured
by flow cytometry using a LSR-II FACS machine (BD Bioscience)
and analyzed using FACS Diva Software (BD Bioscience).
Immunizations
Groups of six C57BL/6 mice were immunized on day 1 and
boosted on day 28 by i.m. route (biceps femoris) using a 25G
needle. Per dose, 100 ml/mouse were injected containing either
50 mg of OVA alone or OVA add-mixed with 1610
8 nrMVA as
adjuvant. Negative controls received PBS. Serum samples were
collected from blood of the tail vein 1 day before each
immunization and 1 week after the last immunization, when the
mice were killed by CO2 inhalation. Sera were stored at 220uC
prior to determination of Ag-specific Abs.
Detection of Ag-specific Abs
OVA-specific Abs were determined by ELISA, as previously
described [49]. Briefly, 96-well Immuno MaxiSorp plates (Nunc,
Roskilde, Denmark) were coated overnight at 4uC with 100 mlo f
OVA with a concentration of 5 mg/ml in carbonate buffer
(pH 9.6). Then, the wells were blocked, and plates were washed
and further incubated with 100 ml of serial two-fold dilutions of
sera at 37uC for 1 h. After four washes, the biotinylated c-chain
specific goat anti-mouse detection Ab (Sigma Chemie, Deisenho-
fen, Germany) was added. The plates were further incubated at
37uC for 1 h. After the plates were washed, peroxidase-conjugated
streptavidin (PharMingen) was added and the plates were
incubated at 37uC for 45 min. After another four washes, the
reaction was developed using ABTS in 0.1 M citrate-phosphate
buffer (pH 4.35) containing 0.01% H2O2, and the absorbance was
read at a wavelength of 405 nm. The IgG isotypes present in the
serum samples were determined by an ELISA using as secondary
Abs biotin-conjugated rat anti-mouse IgG1 and IgG2c (Southern
Biotechnology Associates, Birmingham, AL). The absorbance
values were plotted against the dilutions, and the endpoint titers
were determined as the highest sample dilution that gave an A405
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Determination of IFN-c in supernatants of re-stimulated
splenocytes
To quantify the IFN-c secreted by splenocytes re-stimulated in
vitro using OVA protein, supernatants were collected on day 4 and
stored at 270uC until processing. Then, the concentration of IFN-
c was measured using the mouse Th1/Th2 BD Cytokine Bead
Array (BD Bioscience), according to the manufacturer’s instruc-
tions.
Detection of IFN-c-, IL-4- and IL-2-producing cells
The numbers of IFN-c-, IL-4-, and IL-2-secreting cells in the
spleen and BM of immunized mice were determined by ELISPOT
assay, according to the manufacturer’s instructions (Becton
Dickinson). Briefly, polyvinylidene difluoride plates (Millipore,
Bedford, MA) were coated with anti-IFN-c or anti-IL-2 or anti-IL-
4 specific capture antibodies (100 ml/well). After washing and
blocking, cells (1610
6 cells/well) were incubated in triplicate in the
absence or presence of MHC class I restricted OVA peptide (for
IFN-c) or OVA (for IL-4 and IL-2) for 16 h and 48 h, respectively.
Then, plates were washed and 100 ml of the corresponding
biotinylated detection antibody was added to each well, and plates
were incubated for 1 h at room temperature. After several washes,
the plates were further incubated for 1 h with 100 ml/well of
peroxidase-conjugated streptavidin (BD Pharmingen, Germany).
The spots were developed by using 3-amino-9-ethylcarbazole
(Sigma) in 0.1 M acetate buffer (pH 5.0) and 0.05% H2O2. The
reaction was stopped by rinsing the plates with tap water, and the
plates were air-dried. The spots were scanned with a CTL
ELISPOT reader (ImmunoSpot series 3A) and were counted by
using ImmunoSpot image analyzer software v3.2.
Detection of IgG-secreting cells
The numbers of total and Ag-specific IgG secreting cells in the
BM of immunized mice were determined by ELISPOT assay.
Briefly, polyvinylidene difluoride plates (Millipore, Bedford, MA)
were coated with either 100 ml/well of anti-IgG capture Ab
(Sigma, Germany) or OVA (5 mg/ml) to determine total and Ag-
specific Abs-secreting cells, respectively. Different concentrations
of BM cells were incubated in quadruplicate for 6 h. Then, the
plates were washed, 100 ml of the biotinylated detection Ab (anti-
IgG, Sigma) was added to each well, and the plates were incubated
at 4uC overnight. After several washes, the plates were incubated
for 1 h with 100 ml/well of peroxidase-conjugated streptavidin
(BD Pharmingen, Germany) and then processed as described
above.
In vivo killing assay
Suspensions of splenocytes from naı ¨ve C57BL/6 mice were
depleted of red blood cells and split into two equal portions. One
portion was labeled with a high concentration (1 mM) of CFSE
(CFSE
hi; Molecular Probes) and incubated at 37uC for 1 h with
the dominant OVA peptide (amino acids 257 to 264) at a
concentration of 15 mg/ml. The other portion was labeled with a
low concentration (0.1 mM) of CFSE (CFSE
lo) and was further
incubated at 37uC for 1 h without peptide. Equal numbers of each
cell population were mixed. A total amount of 2610
7 cells was
adoptively transferred by i.v. injection into the immunized mice.
Cells from the spleen were analyzed by flow cytometry after 16 h
with a FACSCalibur interfaced with BD Cell Quest Pro software.
The percentage of OVA-specific lysis was determined by the loss
of the peptide-pulsed CFSE
hi population and compared to the
control CFSE
lo population. The following formula was used to
calculate the percentage of specific lysis: 1002{[(% CFSE
hi in
immunized mice/% CFSE
lo in immunized mice)/(% CFSE
hi in
control mice/% of CFSE
lo in control mice)]6100}.
Statistical analysis
Statistical analysis was performed using the software GraphPad
Prism version 5.02 for Windows. The significance of the
differences observed between three or more groups was deter-
mined using the one-way ANOVA followed by the Turkey-
Kramer post test. Differences were considered significant at
p,0.05.
Supporting Information
Figure S1 Schematic representation of the viability and
activation levels of non-infected and nrMVA-infected DCs at
different MOIs. The MOI of 0.05, 0.5 and 5 were arbitrarily
considered as representative of low, intermediate and high MOI,
respectively.
Found at: doi:10.1371/journal.pone.0011400.s001 (0.15 MB TIF)
Figure S2 Comparison of immune responses induced by OVA
using nrMVA as adjuvant and rMVA-OVA P7.5. (A) OVA-
specific serum IgG titers. Each bar represents the group mean end-
point titer, the SEM is indicated by vertical lines. (B) OVA specific
IFN-c secreting CD8
+ T cells. Splenocytes of immunized mice
were re-stimulated in vitro for 16 h with the dominant MHC class I
restricted peptide SIINFEKL. Results are presented as specific
spot forming units (SFU)/1610
6 cells. The SEM of quadruplicate
values is indicated by vertical lines. The values reported are those
obtained from stimulated cells subtracted of background from
non-stimulated cells. Values of non-stimulated cells were lower
than 50 SFU/1610
6 cells. The results were statistically significant
at p,0.001 (**); p,0.0001 (***).
Found at: doi:10.1371/journal.pone.0011400.s002 (0.89 MB TIF)
Figure S3 Long lasting IgG specific are maintained by BM Ab-
secreting cells in mice immunized with OVA and nrMVA. BM
total IgG secreting cells or BM OVA-specific IgG secreting cells
from mice vaccinated with nrMVA alone or OVA alone or OVA
add-mixed with nrMVA were measured by ELISPOT. One
representative ELISPOT well from each group is shown. The total
number of spots is indicated in the upper left quadrant of each
panel.
Found at: doi:10.1371/journal.pone.0011400.s003 (2.75 MB TIF)
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